Restricted accessResearch articleFirst published online 2021-02
Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy
WirthLJ, ShermanS, DrilonA, SolomonBJ, RobinsonB, LorchJ, McCoachC, PatelJD, LeboulleuxS, WordenF, OwonikokoTK, BroseMS, TaylorMH, ItalianoA, GautschiO, GarciaM, RothenbergSM, SubbiahV, ShahM, CabanillasM. 2019. Registrational results of LOXO-292 in patients with RET-altered thyroid cancers ESMO 2019 Congress. Ann Oncol, 30(Suppl. 5):v851–v934.
2.
SolomonBJ, TanL, LinJJ, WongSQ, HollizeckS, EbataK, TuchBB, YodaS, GainorJF, SequistLV, OxnardGR, GautschiO, DrilonA, SubbiahV, KhooC, ZhuEY, NguyenM, HenryD, CondroskiKR, KolakowskiGR, GomezE, BallardJ, MetcalfAT, BlakeJF, DawsonSJ, BlosserW, StancatoLF, BrandhuberBJ, AndrewsS, RobinsonBG, RothenbergSM. 2020. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J Thorac Oncol, 15:541–549.
3.
LiuX, ShenT, MooersBHM, HilbergF, WuJ. 2018. Drug resistance profiles of mutations in the RET kinase domain. Br J Pharmacol, 175:3504–3515.
4.
Dagogo-JackI, StevensSE, LinJJ, NagyR, FerrisL, ShawAT, GainorJF. 2018. Emergence of a RET V804M gatekeeper mutation during treatment with vandetanib in RET-rearranged NSCLC. J Thorac Oncol, 13:e226–e227.
